The treatment of progressive ovarian carcinoma with D-Trp-LHRH (decapeptyl)

in preventing delayed emesis: complete or major control of vomiting in 86100% of patients of both treatment groups (Table 1). There were no noteworthy changes in clinical and laboratory parameters. Headache, asthenia or sedation were reported by 6 patients receiving tropisetr’on and by 4 receiving alixapride. In conclusion, our results confirm that tropisetron is a welltolerated and manageable anti-emetic drug. Its efficacy is superior to that of alizapride, at least in the control of acute emesis.